Endothelin receptor antagonists and cardiovascular diseases of aging.
Our understanding of the role of the endothelin system in human cardiovascular physiology and pathophysiology has evolved very rapidly since the initial description of its constituent parts in 1988. Endothelin-1 (ET-1) is the predominant endothelin isoform in the human cardiovascular system and has potent vasoconstrictor, mitogenic and antinatriuretic properties which have implicated it in the pathophysiology of a number of cardiovascular diseases. The effects of ET-1 have been shown to be mediated by 2 principal endothelin receptor subtypes: ET(A) and ET(B). The development of a range of peptidic and nonpeptidic endothelin receptor antagonists represents an exciting breakthrough in human cardiovascular therapeutics. Two main classes of endothelin receptor antagonist have been developed for possible human therapeutic use: ET(A)-selective and nonselective antagonists. Extensive laboratory and clinical research with these agents has highlighted their promise in various cardiovascular diseases. Randomised, placebo-controlled clinical trials have yielded very encouraging results in patients with hypertension and chronic heart failure with more preliminary data suggesting a possible role in the treatment and prevention of atherosclerosis and stroke. Much more research is needed, however, before endothelin receptor antagonists can be considered for clinical use.
Love
M P
MP
Department of Medical Cardiology, Glasgow Royal Infirmary, Scotland. MLove39495@aol.com
McMurray
J J
JJ
D000368:Aged; D000828:Animal Population Groups; D000818:Animals; D001161:Arteriosclerosis / Q000188:drug therapy; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D015507:Drugs, Investigational / Q000627:therapeutic use; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000378:metabolism*; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D006976:Hypertension, Pulmonary / Q000209:etiology; D017466:Receptors, Endothelin / Q000627:therapeutic use; D020521:Stroke / Q000188:drug therapy
D015507:Drugs, Investigational; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D017466:Receptors, Endothelin